SANDOZ AG

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 52203
 
  
 
C07D HETEROCYCLIC COMPOUNDS 46116
 
  
 
C07K PEPTIDES 16120
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 16151
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1485
 
  
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 13125
 
  
 
C07F ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM, OR TELLURIUM 664
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 693
 
  
 
A61J CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 525
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 392

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0023,067 Method For Producing A Recombinant Protein Of InterestFeb 09, 16Jan 25, 18[C12P, C12N]
2018/0008,624 Pharmaceutical Compositions Comprising Ledipasvir And SofosbuvirFeb 10, 16Jan 11, 18[A61K]
2017/0342,422 Sequence VariantsDec 18, 15Nov 30, 17[C12Q, C12N]
2017/0326,153 Pharmaceutical Composition Consisting of Ceftaroline Fosamil Acetic Acid Solvate Particles Arginine Particles, Both Having A Specific Particle Size DistributionOct 27, 15Nov 16, 17[A61K]
2017/0327,504 Synthesis of Substituted 1H-Pyrazolo[3,4-D]PyrimidinesOct 28, 15Nov 16, 17[C07D]
2017/0313,735 Improved Fluorination ProcessJun 22, 15Nov 02, 17[C07H]
2017/0296,570 High Drug Load Tablets Comprising SofosbuvirOct 08, 15Oct 19, 17[A61K]
2017/0258,761 Pharmaceutical Compositions Comprising CanagliflozinAug 28, 15Sep 14, 17[A61J, A61K, B65D]
2017/0231,969 Pharmaceutical Compositions of EdoxabanMay 13, 15Aug 17, 17[A61K]
2017/0233,330 Process for the preparation of 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]-phenolAug 11, 15Aug 17, 17[C07C]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9867829 Stable pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereofAug 12, 13Jan 16, 18[A61J, A61K, B65D]
9850254 -(p-tolyl) groupsMay 30, 14Dec 26, 17[C07D]
9815879 Method for the purification of G-CSFJul 14, 06Nov 14, 17[G01N, C07K]
9745588 Transcription terminator sequencesJun 01, 12Aug 29, 17[C07H, C12N]
9730932 Pharmaceutical composition containing crystalline macitentanApr 17, 14Aug 15, 17[A61J, A61K, B65D]
9725454 Crystalline forms of ponatinib hydrochlorideJul 04, 14Aug 08, 17[A61K, C07D]
9683252 Method for producing a recombinant protein on a manufacturing scaleMay 16, 08Jun 20, 17[C12P, C12N]
9677107 technologyDec 19, 13Jun 13, 17[C12P, C12N]
9629810 Capsule with soluble blocking elementSep 09, 09Apr 25, 17[A61J, A61K, A47G, A61M]
9598718 Quantification of misfolded TNFR2:FcAug 08, 14Mar 21, 17[C12Q, G01N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0369,475 Flibanserin HydrateAbandonedJun 23, 16Dec 28, 17[C07D]
2017/0166,570 PREPARATION OF ERTAPENEM INTERMEDIATESAbandonedJan 17, 17Jun 15, 17[C07D]
2016/0346,267 Pharmaceutical Composition Comprising ApixabanAbandonedFeb 16, 15Dec 01, 16[A61K]
2016/0340,384 METHOD FOR REFOLDING RECOMBINANTLY PRODUCED POLYPEPTIDESAbandonedDec 22, 14Nov 24, 16[A61K, C12N, C07K]
2016/0264,628 PREPARATION OF MICAFUNGIN INTERMEDIATESAbandonedMay 23, 16Sep 15, 16[C07K]
2016/0185,792 METHOD FOR THE PURIFICATION OF EPOTHILONES VIA CRYSTALLIZATIONAbandonedAug 18, 14Jun 30, 16[C07D]
2016/0185,793 METHOD FOR THE PURIFICATION OF EPOTHILONES VIA CRYSTALLIZATIONAbandonedAug 18, 14Jun 30, 16[C07D]
2016/0106,679 TABLET WITH INCREASED DRUG LOAD OF ODANACATIBAbandonedMay 16, 14Apr 21, 16[A61K]
2016/0081,937 TABLET WITH INCREASED DRUG LOAD OF ODANACATIBAbandonedMay 16, 14Mar 24, 16[A61K]
2016/0039,871 NOVEL FORMS OF TELAPREVIRAbandonedDec 20, 13Feb 11, 16[C07K]
2015/0361,139 CRYSTALLINE FORM OF LINACLOTIDEAbandonedJan 28, 14Dec 17, 15[C07K]
2015/0038,677 PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOFAbandonedMar 15, 13Feb 05, 15[C07K]
2015/0038,727 METHOD FOR PREPARING SILODOSINAbandonedOct 19, 12Feb 05, 15[C07D]
2014/0329,989 PREPARATION OF MICAFUNGIN INTERMEDIATESAbandonedSep 07, 12Nov 06, 14[C07F, C07D, C07K]
2014/0194,356 AQUEOUS FORMULATION COMPRISING AT LEAST A NEUTRAL SALT AND A BIOPHARMACEUTICAL PROTEINAbandonedJul 25, 12Jul 10, 14[A61K]
2014/0170,701 METHOD FOR PRODUCING A RECOMBINANT PROTEIN OF INTERESTAbandonedDec 19, 13Jun 19, 14[C12P, C12N]
2014/0163,083 NOVEL CRYSTALLINE SALTS OF ASENAPINEAbandonedMay 15, 12Jun 12, 14[C07D]
8546112 Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid esterExpiredMay 19, 09Oct 01, 13[C12P]
8536305 Processes for preparing a polypeptideExpiredSep 27, 07Sep 17, 13[A61K, C07K]
8481758 Process for the production of prostaglandins and prostaglandin analogsExpiredJul 10, 09Jul 09, 13[C07D, C07C]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.